Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35830649

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
N Engl J Med
Publication date
2022 Jul 28
First author
Ansell SM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 Jul 28;387(4):370-372. doi: 10.1056/NEJMe2207639.
    note
    Source null
    related pmid
    35830618
    relationship
    Comment in
  2. citation
    N Engl J Med. 2022 Oct 20;387(16):1527. doi: 10.1056/NEJMc2211125.
    note
    Source null
    related pmid
    36260800
    relationship
    Comment in

Authors and identifiers

  1. name
    Ansell SM
    type
    Author
  2. name
    Radford J
    type
    Author
  3. name
    Connors JM
    type
    Author
  4. name
    Długosz-Danecka M
    type
    Author
  5. name
    Kim WS
    type
    Author
  6. name
    Gallamini A
    type
    Author
  7. name
    Ramchandren R
    type
    Author
  8. name
    Friedberg JW
    type
    Author
  9. name
    Advani R
    type
    Author
  10. name
    Hutchings M
    type
    Author
  11. name
    Evens AM
    type
    Author
  12. name
    Smolewski P
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Ansell SM
    type
    Author
  2. name
    Radford J
    type
    Author
  3. name
    Connors JM
    type
    Author
  4. name
    Długosz-Danecka M
    type
    Author
  5. name
    Kim WS
    type
    Author
  6. name
    Gallamini A
    type
    Author
  7. name
    Ramchandren R
    type
    Author
  8. name
    Friedberg JW
    type
    Author
  9. name
    Advani R
    type
    Author
  10. name
    Hutchings M
    type
    Author
  11. name
    Evens AM
    type
    Author
  12. name
    Smolewski P
    type
    Author
bibliography ids
  1. nci-bib-35c7e2fb3a4f814c2eebd443
book metadata
content sha256
ab93fd99b5076cf0cde25accf91313c8da6072e937140b6c8ed95d03d8e60beb
document type
citation
dois
  1. 10.1056/NEJMoa2206125
electronic publication date
display
2022 Jul 13
precision
day
year
2022
evidence scope
bibliographic_metadata_only
id
pubmed:35830649
immutable id
pubmed:35830649@ab93fd99b5076cf0cde25accf91313c8da6072e937140b6c8ed95d03d8e60beb
journal
abbreviation
N Engl J Med
issn electronic
1533-4406
issn print
0028-4793
issue
4
name
The New England journal of medicine
nlm unique id
0255562
pages
310-320
volume
387
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    N Engl J Med. 2022 Jul 28;387(4):370-372. doi: 10.1056/NEJMe2207639.
    note
    Source null
    related pmid
    35830618
    relationship
    Comment in
  2. citation
    N Engl J Med. 2022 Oct 20;387(16):1527. doi: 10.1056/NEJMc2211125.
    note
    Source null
    related pmid
    36260800
    relationship
    Comment in
outcomes validated
false
pmid
35830649
provenance
batch id
9d150d55960e0c12aada
provider
NCBI PubMed ESummary
record sha256
df28ed66b53cd5f9c6a9333364e9fdea6a427305533eb8c2c72f6a6a2fee0ac9
response sha256
2d4ef1cc8137eef6e7216f66bf8601c3899bc663b8626f412794d39585de6b6b
retrieved at
2026-09-09T23:48:09.820498+00:00
publication date
display
2022 Jul 28
precision
day
year
2022
publication types
  1. Comparative Study
  2. Journal Article
  3. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35830649/
title
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.

Preserved source evidence · Not medical advice